Polarean Imaging plc (PLLWF)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 1 | 1 | 1 | 3 | - | 3 | 6 |
| Operating profit | $m | -9 | -10 | ||||||
| Net profit | $m | -7 | -14 | -14 | -12 | -9 | - | -10 | -10 |
| EPS reported | $ | -0.01 | -0.01 | ||||||
| Operating cashflow per share | $ | -0.00 | -0.01 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.00 | -0.01 | ||||||
| Free cash flow | $m | -6 | -8 | ||||||
| Net debt | $m | -12 | -7 | ||||||
| Book value equity | $m | 12 | 8 | ||||||
| Book value per share | $ | 0.01 | 0.01 | ||||||
| Number of shares | m | 1,207.03 | 1,207.03 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.49 | 0.07 | ||||||
| P/S LTM | x | 5.86 | 0.53 | ||||||
| P/FCF LTM | x | -3.12 | -0.30 | ||||||
| EV/EBITDA LTM | x | -0.86 | 1.74 | ||||||
| EV/Sales LTM | x | 2.10 | -4.27 | ||||||
| Earnings Yield LTM | % | -47.17% | -8.36% | ||||||
| FCF Yield | % | -32.06% | -653.18% | ||||||
| Quality | |||||||||
| ROE | % | -70.33% | -65.39% | ||||||
| ROIC | % | -68.23% | -53.40% | ||||||
| Operating margin | % | -2.83% | -2.83% | ||||||
| Gross margin | % | +46.06% | +14.83% | ||||||
| FCF/Sales | % | -187.88% | -178.99% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +246.82% | -15.86% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -11.52 | -19.07 | ||||||
| Net Debt/EBITDA | x | 1.54 | 1.96 | ||||||
| EBIT/Net interest | x | -540.82 | -540.85 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -1.00 | -0.87 | ||||||
| Gross debt/equity | x | 0.04 | 0.06 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Polarean Imaging plc operates as a specialized entity within the medical imaging sector, focusing on integrated drug-device solutions. The company extends its services across international markets, including the United States, Canada, Germany, and the United Kingdom. At its core, Polarean is engaged in the creation and market introduction of advanced gas polarizer systems and associated ancillary instruments. A significant aspect of their innovation lies in developing specialized equipment that enhances conventional magnetic resonance imaging (MRI) machines, enabling them to perform advanced functional pulmonary imaging. The company distinguishes itself by specializing in the application of hyperpolarized xenon gas (129Xe) as a unique imaging agent. This technology allows for the detailed visualization of regional ventilation and gas exchange within the lungs, particularly in the smallest airways, the interface between the lung tissue and the bloodstream, and the pulmonary vasculature, thereby offering a novel diagnostic method. Furthermore, Polarean Imaging plc is actively involved in the design and manufacturing of the specific MRI radiofrequency coils that are indispensable for imaging 129Xe within an MRI system. Established in 2016, the company's base of operations is located in Durham, North Carolina.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Polarean Imaging plc operates as a specialized entity within the medical imaging sector, focusing on integrated drug-device solutions. The company extends its services across international markets, including the United States, Canada, Germany, and the United Kingdom. At its core, Polarean is engaged in the creation and market introduction of advanced gas polarizer systems and associated ancillary instruments. A significant aspect of their innovation lies in developing specialized equipment that enhances conventional magnetic resonance imaging (MRI) machines, enabling them to perform advanced functional pulmonary imaging. The company distinguishes itself by specializing in the application of hyperpolarized xenon gas (129Xe) as a unique imaging agent. This technology allows for the detailed visualization of regional ventilation and gas exchange within the lungs, particularly in the smallest airways, the interface between the lung tissue and the bloodstream, and the pulmonary vasculature, thereby offering a novel diagnostic method. Furthermore, Polarean Imaging plc is actively involved in the design and manufacturing of the specific MRI radiofrequency coils that are indispensable for imaging 129Xe within an MRI system. Established in 2016, the company's base of operations is located in Durham, North Carolina.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free